Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | Perioperative Medicine

Fig. 1

From: Impact on grafted kidney function of rocuronium-sugammadex vs cisatracurium-neostigmine strategy for neuromuscular block management. An Italian single-center, 2014-2017 retrospective cohort case-control study

Fig. 1

Box plots comparing sugammadex to neostigmine on kidney function before and after surgery. Boxes represent the median and IQR. “Whiskers” (minimum and maximum marks) represent values 1.5 times the IQR [(1st quartile–1.5 × IQR) and (3rd quartile+1.5 × IQR)]. IQR interquartile range, p p value with significance set at < 0.05, NEO group of patients receiving neostigmine for reversal of cisatracurium-induced neuromuscular block (NMB), SUG group of patients receiving sugammadex for reversal of rocuronium-induced NMB, PRE baseline value (before kidney transplantation), POST first measurement obtained the day of kidney transplantation, creatinine and urea serum creatinine and serum urea, eGRF estimated glomerular filtration rate

Back to article page

Perioperative Medicine

ISSN: 2047-0525